Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes
Status:
Completed
Trial end date:
2019-06-15
Target enrollment:
Participant gender:
Summary
The role of individual leukocyte populations in type 2 diabetes (T2D) and immunometabolism in
general represent important gaps in knowledge to better understand the etiopathogenesis of
T2D. Emerging evidence indicates that certain leukocyte populations serve as an important
nexus of T2D-associated inflammation. This novel and innovative clinical trial will test the
efficacy of a leukocyte-selective anti-inflammatory small drug as adjunctive therapy in
improving insulin sensitivity in obese, insulin-resistant type 2 diabetic subjects. This
trial also offers a first-in-kind opportunity to better understand the role of specific
leukocyte populations in type 2 diabetes. The drug's clinical profile suggests that it will
be well-tolerated with few, if any, side effects, and the existence of simple methods that
can indirectly measure its activity in vivo
Phase:
Phase 2
Details
Lead Sponsor:
Nick Giannoukakis, PhD
Collaborators:
AstraZeneca National Institutes of Health (NIH) University of Pittsburgh University of South Florida